Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × Platinum Compounds × 1 year × Clear all

NCT05363319 2026-03-18

CEMI-LUNG

Carcinoma, Non-Small-Cell Lung

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07416474 2026-02-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06465329 2026-02-12

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04585477 2026-02-10

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04486833 2026-01-21

Acclaim-1

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04966676 2026-01-08

ATLAS

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT07141563 2026-01-07

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Carcinoma, Non-Small-Cell Lung

NCT07320105 2026-01-06

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

Phase 4 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05614102 2026-01-05

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06216301 2025-12-17

LUNAR-2

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04765709 2025-12-16

BRIDGE

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT07170995 2025-11-18

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07084610 2025-08-22

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07063329 2025-07-25

Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05607550 2025-06-22

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06908733 2025-04-03

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung